公开(公告)号：US10995091B2

公开(公告)日：2021-05-04

申请号：US16167084

申请日：2018-10-22

申请人： Proximagen, LLC

发明人： Edward Daniel Savory ,  Alison Stewart ,  Allison Carley ,  Giles Brown ,  Iain Simpson ,  Kathryn Oliver ,  Lee Patient ,  Michael Higginbottom ,  Andrew Graham Cole

IPC分类号： A61K31/55 ,  A61K31/551 ,  A61K31/439 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/12 ,  C07D401/12 ,  C07B59/00 ,  C07D401/04 ,  C07D413/12 ,  C07D417/12

摘要： The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

公开(公告)号：US20200262835A1

公开(公告)日：2020-08-20

申请号：US16784320

申请日：2020-02-07

申请人： PROXIMAGEN, LLC

发明人： Max ESPENSEN ,  Lee PATIENT ,  David EVANS ,  Edward SAVORY ,  Iain SIMPSON

IPC分类号： C07D471/04 ,  A61K31/40 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/501 ,  A61K31/506 ,  C07C53/18

摘要： Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.

公开(公告)号：US10428066B2

公开(公告)日：2019-10-01

申请号：US15911935

申请日：2018-03-05

申请人： PROXIMAGEN, LLC

发明人： Max Espensen ,  Lee Patient ,  David Evans ,  Iain Simpson ,  Edward Savory

IPC分类号： A61K31/40 ,  C07D471/04 ,  C07C53/18

摘要： The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.

公开(公告)号：US11311552B2

公开(公告)日：2022-04-26

申请号：US15562741

申请日：2016-04-01

申请人： PROXIMAGEN, LLC

发明人： Peter Richardson ,  Jacqueline Mary Walling ,  Claudio Festuccia

IPC分类号： A61K31/551 ,  A61K9/00 ,  A61K45/06

摘要： The invention relates to 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, for use in treatment of CNS cancers. The invention also relates to combination treatments with irradiation and/or a chemotherapeutic agent for use in the treatment of cancer.

公开(公告)号：US20200147059A1

公开(公告)日：2020-05-14

申请号：US16620373

申请日：2018-06-08

申请人： Proximagen, LLC

发明人： William PULLMAN

IPC分类号： A61K31/437 ,  A61K31/15 ,  A61K31/198 ,  A61K31/165

摘要： Inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, are useful for the prevention and/or treatment of migraine, including headache, chronic migraine, episodic migraine, medication overuse headache disorder (MOU), migraine without aura, migraine with aura, migraine aura without headache, ocular migraine, vestibular migraine, basilar migraine, hemiplegic migraine, ophthalmoplegic migraine, and tension-type headache (TTH).

公开(公告)号：US20200002335A1

公开(公告)日：2020-01-02

申请号：US16542792

申请日：2019-08-16

申请人： PROXIMAGEN, LLC

发明人： Max ESPENSEN ,  Lee PATIENT ,  David EVANS ,  Iain SIMPSON ,  Edward SAVORY

IPC分类号： C07D471/04 ,  A61K31/40 ,  C07C53/18

摘要： The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.

公开(公告)号：US10155761B2

公开(公告)日：2018-12-18

申请号：US15497324

申请日：2017-04-26

申请人： PROXIMAGEN, LLC

发明人： Edward Daniel Savory ,  Alison Stewart ,  Allison Carley ,  Giles Brown ,  Iain Simpson ,  Kathryn Oliver ,  Lee Patient ,  Michael Higginbottom ,  Andrew Graham Cole

IPC分类号： A61K31/55 ,  A61K31/551 ,  A61K31/439 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/12 ,  C07D401/12 ,  C07B59/00 ,  C07D401/04 ,  C07D413/12 ,  C07D417/12

摘要： The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

公开(公告)号：US20230190728A1

公开(公告)日：2023-06-22

申请号：US17913379

申请日：2021-03-25

申请人： PROXIMAGEN, LLC

发明人： William Pullman ,  Peter Van Ess

IPC分类号： A61K31/4545 ,  A61P29/00 ,  A61P11/00 ,  A61P31/14 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/551

CPC分类号： A61K31/4545 ,  A61K31/496 ,  A61K31/551 ,  A61K31/5377 ,  A61P11/00 ,  A61P29/00 ,  A61P31/14

摘要： The present invention relates to the treatment and prevention of pulmonary inflammation using a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, and/or prodrug thereof. The pulmonary inflammation may be associated with acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), which in turn may be associated with viral induced cytokine surge. Such diseases and conditions may be caused by a coronavirus, i.e., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), or Middle East respiratory syndrome coronavirus (MERS-CoV). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US11530208B2

公开(公告)日：2022-12-20

申请号：US15506847

申请日：2015-09-17

申请人： PROXIMAGEN, LLC

发明人： Lee Patient ,  Iain Simpson ,  Edward Savory

IPC分类号： C07D471/04 ,  C07D403/04 ,  C07D403/14 ,  A61K31/436 ,  A61K31/437

摘要： A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R1, W, V, and R3 are as defined in claim 1.

公开(公告)号：US10968223B2

公开(公告)日：2021-04-06

申请号：US16933417

申请日：2020-07-20

申请人： PROXIMAGEN, LLC

发明人： Max Espensen ,  Lee Patient ,  David Evans ,  Iain Simpson ,  Edward Savory

IPC分类号： C07D471/04 ,  A61K31/40 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/501 ,  A61K31/506 ,  C07C53/18

摘要： A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia)